Gene analysis and clinical features of MYH9-related disease

Objective: To identify gene variants and investigate clinical features of nonmuscle myosin heavy chain 9-related disease (MYH9-RD). Methods: In this retrospective study, the data of patients with MYH9-RD admitted to Shenzhen Children's Hospital from July 2017 to September 2020 were extracted. T...

Ausführliche Beschreibung

Bibliographische Detailangaben
Veröffentlicht in:Zhonghua er ke za zhi = Chinese journal of pediatrics. - 1960. - 59(2021), 11 vom: 02. Nov., Seite 957-962
1. Verfasser: Luo, X J (VerfasserIn)
Weitere Verfasser: Cao, K, Liu, J, Duan, Q Y, Chen, S Y, Zhang, Y, Huang, T, Mao, X N, Li, C G, Chen, Y S
Format: Online-Aufsatz
Sprache:Chinese
Veröffentlicht: 2021
Zugriff auf das übergeordnete Werk:Zhonghua er ke za zhi = Chinese journal of pediatrics
Schlagworte:Journal Article MYH9 protein, human Molecular Motor Proteins Myosin Heavy Chains EC 3.6.4.1
LEADER 01000naa a22002652 4500
001 NLM332493512
003 DE-627
005 20231225215703.0
007 cr uuu---uuuuu
008 231225s2021 xx |||||o 00| ||chi c
024 7 |a 10.3760/cma.j.cn112140-20210507-00389  |2 doi 
028 5 2 |a pubmed24n1108.xml 
035 |a (DE-627)NLM332493512 
035 |a (NLM)34711031 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a chi 
100 1 |a Luo, X J  |e verfasserin  |4 aut 
245 1 0 |a Gene analysis and clinical features of MYH9-related disease 
264 1 |c 2021 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 01.11.2021 
500 |a Date Revised 31.05.2022 
500 |a published: Print 
500 |a Citation Status MEDLINE 
520 |a Objective: To identify gene variants and investigate clinical features of nonmuscle myosin heavy chain 9-related disease (MYH9-RD). Methods: In this retrospective study, the data of patients with MYH9-RD admitted to Shenzhen Children's Hospital from July 2017 to September 2020 were extracted. The gene variants, clinical features and laboratory tests results were summarized. Results: Among the 6 children, 4 were males and 2 were females, aged 4.0 (0.5-7.6) years. Main clinical manifestations included thrombocytopenia (6 cases), epistaxis (3 cases), petechias (2 cases), traumatic hematoma (1 case), and abnormal liver enzymes (1 case). One patient had no family history, and the other 5 cases were pedigrees. Two pedigrees (2 cases) had long-term microscopic hematuria, one pedigree (2 cases) had history of early cataract, and three pedigrees (5 cases) had chronic mild elevation of liver enzymes. Four MYH9 gene variants were found in 12 patients, including c.2104C>T(p.R702C) in exon 17, c.4270G>A(p.D1424N) in exon 31, c.5521G>A (p.E1841K) in exon 39, and c.5797C>T (p.R1933X) in exon 41. According to the family pedigrees analysis, except for the case of variant in exon 17 which was spontaneous mutation with no family history, the other variants were from their father or mother. The complete blood count results showed a decreased platelet number in these patients, and the counting results of the automated hematology analyzer were significantly lower than that of manual counting method ((33.4±17.2) × 10⁹ vs. (60.4±21.0) × 109/L,t=-5.83, P<0.05). The examination of the peripheral blood smear revealed the presence of thrombocytopenia with giant platelets and granulocyte inclusion bodies. The MYH9 gene variant (R702C) located at the N-terminus head domain of non-muscle myosin heavy chain ⅡA (NMMHC-ⅡA), which has ATPase activity, led to severe reduction of platelet number (<20×109/L) and obscure granulocyte inclusion bodies. However, higher platelet numbers (40×109-80×109/L) and obvious granulocyte inclusion bodies were observed in patients with tail-position mutations at C-terminus. Conclusions: The clinical phenotypes of MYH9-RD were variable. The mutations in certain regions of MYH9 gene were related to platelet count and granulocyte inclusion bodies. MYH9-RD should be considered in individuals with unknown etiology and persistent thrombocytopenia which is non-responsive to conventional treatment, regardless of family history. Complete blood count and blood smear morphology examinations are the first steps to screen and diagnose the disease. The laboratory should pay attention to the morphological review rules and standardized reports 
650 4 |a Journal Article 
650 7 |a MYH9 protein, human  |2 NLM 
650 7 |a Molecular Motor Proteins  |2 NLM 
650 7 |a Myosin Heavy Chains  |2 NLM 
650 7 |a EC 3.6.4.1  |2 NLM 
700 1 |a Cao, K  |e verfasserin  |4 aut 
700 1 |a Liu, J  |e verfasserin  |4 aut 
700 1 |a Duan, Q Y  |e verfasserin  |4 aut 
700 1 |a Chen, S Y  |e verfasserin  |4 aut 
700 1 |a Zhang, Y  |e verfasserin  |4 aut 
700 1 |a Huang, T  |e verfasserin  |4 aut 
700 1 |a Mao, X N  |e verfasserin  |4 aut 
700 1 |a Li, C G  |e verfasserin  |4 aut 
700 1 |a Chen, Y S  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Zhonghua er ke za zhi = Chinese journal of pediatrics  |d 1960  |g 59(2021), 11 vom: 02. Nov., Seite 957-962  |w (DE-627)NLM136249191  |x 0578-1310  |7 nnns 
773 1 8 |g volume:59  |g year:2021  |g number:11  |g day:02  |g month:11  |g pages:957-962 
856 4 0 |u http://dx.doi.org/10.3760/cma.j.cn112140-20210507-00389  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_20 
912 |a GBV_ILN_22 
912 |a GBV_ILN_24 
912 |a GBV_ILN_31 
912 |a GBV_ILN_39 
912 |a GBV_ILN_40 
912 |a GBV_ILN_50 
912 |a GBV_ILN_61 
912 |a GBV_ILN_65 
912 |a GBV_ILN_69 
912 |a GBV_ILN_70 
912 |a GBV_ILN_72 
912 |a GBV_ILN_120 
912 |a GBV_ILN_130 
912 |a GBV_ILN_227 
912 |a GBV_ILN_244 
912 |a GBV_ILN_285 
912 |a GBV_ILN_294 
912 |a GBV_ILN_350 
912 |a GBV_ILN_665 
912 |a GBV_ILN_813 
951 |a AR 
952 |d 59  |j 2021  |e 11  |b 02  |c 11  |h 957-962